Summit Therapeutics Inc. Logo

Summit Therapeutics Inc.

Advancing a Phase 3 bispecific antibody for lung cancer and other solid tumors.

SMMT | US

Overview

Corporate Details

ISIN(s):
US86627T1088
LEI:
Country:
United States of America
Address:
601 BRICKELL KEY DRIVE, 33131 MIAMI
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies in oncology. The company aims to address serious unmet medical needs and improve the quality and potential duration of life for patients with difficult cancer diagnoses. Its lead asset is ivonescimab (SMT112), a potential first-in-class, investigational bispecific antibody that combines the effects of immunotherapy (PD-1 blockade) and anti-angiogenesis (VEGF blockade) into a single molecule. Summit is advancing ivonescimab through multiple Phase 3 clinical trials, with an initial focus on non-small cell lung cancer (NSCLC) and plans for expansion into other solid tumors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Summit Therapeutics Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Summit Therapeutics Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Summit Therapeutics Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Devyser Diagnostics Logo
Develops & sells genetic DNA test kits for labs in oncology, transplant & reproductive health.
Sweden
DVYSR
DiaMedica Therapeutics Inc. Logo
Developing a novel protein therapy for acute ischemic stroke and preeclampsia.
United States of America
DMAC
Diamyd Medical AB (publ) Logo
Developing precision immunotherapies to preserve insulin in autoimmune diabetes.
Sweden
DMYD
Dianthus Therapeutics, Inc. /DE/ Logo
Developing selective antibody therapies for severe autoimmune diseases.
United States of America
DNTH
Diasorin Logo
Develops immunodiagnostic and molecular diagnostic kits and systems for healthcare and research.
Italy
DIA
Disc Medicine, Inc. Logo
Developing novel therapies for patients with serious hematologic and rare blood disorders.
United States of America
IRON
DONG-A ST CO.,LTD Logo
Develops and distributes ethical drugs, medical devices, and diagnostics for global healthcare.
South Korea
170900
DongKoo Bio & Pharma Co., Ltd. Logo
Pharma leader in dermatology, developing treatments, probiotics, and investing in biotech therapies.
South Korea
006620
DongKook Life Science Co., Ltd. Logo
A pharmaceutical firm specializing in contrast media for diagnostic imaging and medical devices.
South Korea
303810
DongKookPharmaceuticalCo.,Ltd. Logo
Develops, manufactures, and distributes pharmaceuticals and healthcare products globally.
South Korea
086450

Talk to a Data Expert

Have a question? We'll get back to you promptly.